PTO/SB/08a (08-03)

Approved for use through 073/12006. OMB 0651-0031

U.S. Petents and Trademark Office, U.S. Department of Office (M.S. Department of Committee)

U.S. Petents and Trademark Reduction Act of 1955. Represent on respond to a collection of information anisest (contains a wild OMB control number.

Complete if Known

## Substitute for form 1449A/PTO STRADE INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 4

Sheet

Signature

 a respond to a collection of information aniest is contain a valid OMB control number.

 Complete If Known

 Application Number
 10/591,442

 Filing Date
 September 01, 2006

 First Named Inventor
 Dena LESHKOWITZ

 Art Unit
 1653

 Examiner Name
 Not Yet Assigned

 Attorney Docket Number
 32488

Considered

			U.S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. 1	Document Number	Publication Date DD-MMM-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2 (d known)</sup>			rigines Appear
/CW/	1	US-2002/0009727	24-Jan-2002	Schultz et al.	
	2	US-2003/0036073	20-Feb-2003	Saba	
	3	US-5,202,231	13-Apr-1993	Drmanac et al.	
	4	US-5,525,464	11-Jun-1996	Drmanac et al.	
	5	US-5,695,940	09-Dec-1997	Drmanac et al.	
	6	US-6,410,229	25-Jun-2002	Lockhart et al.	

		FOREIGN	PATENT DOC	UMENTS		
Examiner Initials*	Cite No. 1	Foreign Patent Documents  Country Code <sup>b</sup> Number <sup>a</sup> Kind Code <sup>5</sup> (if known)	Publication Date DD-MMM-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
/CW/	7	PCT WO 95/09248	06-Apr-1995	Drmanac		L
	-					t
			-		-	╁
						İ
_			<del> </del>		-	╁
						L
	-					t
						ļ
	<u></u>	L	<u> </u>	<u> </u>		L
Examin		/Cynthia Wilder/		Date	04/10/2008	

\*EXAMINER: Initial if reference considered, whether or not claims is in conformance with MEDP 980. Dave like through claims in not in conformance and not considered includes copy of copy of the form with next communication to legislate." Applicant's engine claims designation number(s). \*See Kinds Godes of USPTO Patent Documents at wew\_uspts.copy or METP 901 04. \*Enter Office that issued the document, by the two-fetter code (WPDC Standard ST. 3). \*For Japanese patent documents, it is indicated on the very of the region of the Emperor must precorde the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially to governed by 36 U.S. C. 22 and 37 CFR 1.14 this collection is estimated to late 30 to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any commented on the amount of time you require to complete this form and/or suggestions for reducing high burder, should be seen to the Chief Information Officer. U.S. Department of commerce, P.O. 80x 1450, Alexandra, VA. 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

JUN 26 2007

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
spond to a collection of information unless it contains a valid OMB control number.

Considered

Complete if Known

Substitute for form 1449A/PTO

Under the Poperwork Reduction Act of 1995, no per

Signature

	Substitute for form 1449A/PTO				Application Number 10/591,442			
	INFO	DRMATION	DISCLOSUI	Filing Date	September	September 01, 2006		
		TEMENT BY		First Named Inventor	Dena LESHKOWI			
	SIA	I ENLENI D	APPLICA	Group Art Unit	1653			
		(use as many sheet		Examiner Name	Examiner Name Not Yet Assign			
Sheet	eet Of 4			Attorney Docket Number	32488			
		OTHER	PRIOR ART - N	ON PATENT LIT	ERATURE DOCUMENT	rs		
Examiner	Cite	Include name of the	author (in CAPITAL	LETTERS), title of the	article (when appropriate), title	of the item		
Initials No. (book, magazine, journal, serial symposium, catalog, etc.) date, city and/or country where p				nd/or country where pul	blished.		T <sup>2</sup>	
/CW/	8	Cowie et al. "Identification of APC Gene Mutations in Colorectal Cancer Using Universal Microarray-Based Combinatorial Sequencing-by-Hybridization", Human						
		Mutation, 24: 261-271, 2004.  De Saizieu et al. "Bacterial Transcript Imaging by Hybridization of Total RNA to						
- 1	9			cript Imaging by H Biotechnology, 16:		A to		
	10				a Junctional Region is As	spciated		
- 1		with Several Di	fferent VBeta13 S	Subtypes in a Multi	ple Sclerosis Patient atthe	e Onset		
	1			f Diseases, 14:470-				
-	11	Drmanac et al.	Sequencing by H	vbridization (SBH	); Advantages, Achievem	ents and		
- 1	1	Drmanac et al. "Sequencing by Hybridization (SBH): Advantages, Achievements and Opportunities", Biotechnology, 77: 76-101, 2002.						
-	12	Ferrando et al. "Gene Expression Profiling: Will it compement or Replace						
- 1	1 12	Immunophenotyping?", Best Practice & Research Clinical Heamatology, 16(4): 645-						
- 1	1	652, 2003.	ping, , best ria	Aice de Researen e	illinear reconstructory, rec	1,7.0.0		
-	13	Fraser et al. "The VH Gene Repertoire of Splenic B Cells and Somatic Hypermutation						
- 1	13	in Systematic Lupus Erythematosus", Arthritis Research & Therapy, 5(2): 114-121, 2003.						
- 1								
-	14	Frieze et al. "Optimal Reconstruction of a Sequence from its Probes", Journal of						
- 1	14	Computational Biology, 6(3/4): 361-368, 1999.						
$\rightarrow$	15	Gasparotto et al. "Hepatitis C Virus, B-Cell Proliferation and Lymphomas", Leukemia						
- 1	13	Gasparotto et al. "Hepatitis C Virus, is-Cell Proliferation and Lymphomas", Leukenna						
		& Lymphoma, 43(4): 747-751, 2002. Abstract.						
- 1	16	Gerry et al. "Universal DNA Microarray Method for Multiplex Detection of Low						
-		Abundance Point Mutations", J. Mol. Biol., 292: 251-262, 1999.						
	17	Hodges et al. "Diagnostic Role of Tests for T Cell Receptor (TCR) Genes", J Clin Pathol, 56: 1-11, 2003.						
	18	Kienle et al, "VH Mutation Status and VDJ Rearrangement Structure in Mantle Cell						
1		Lymphoma: Correlation With Genomic Aberrations, Clinical Characteristics, and						
- 1	ľ	Outcome", Blood, 102(8):3003-3009, 2003.						
	19	Kienle et al. "Distinct Gene Expression Patterns in Chronic Lymphocytic Leukemia						
1	1.	Defined by Usage of Specific VH Genes", Blood, 107(5):2090-2093, 2006.						
-	20	Kotlan et al. "Immunoglobulin Repertoire of B Lymphocyte Infiltrating Breast						
- 1	20	Medullary Carcinoma", Human Antibodies, 12(4): 113-121, 2003. Abstract.						
	21	Link et al. "Clues to Etiology of Autoimmune Diseases Through Analysis of						
	21							
	100	Immunoglobulin Genes", Arthritis research, 4:80-83, 2002.  Messmer et al. "The Pattern and Distribution of Immunoglobulin VH Gene Mutations						
	22	Messmer et al.	The Pattern and	Distribution of Imi	nullogioculai va Generia	ol .		
		in Chronic Lymphocytic Leukemia B Cells are Consistent With the Canonical Somatic Hypermutation Process", Blood, 103(9):3490-3495, 2004.						
				, Blood, 103(9):34				
Examiner	/Cynthia Wilder/				Date	04/10.	/2008	

EXAMINER: Initial if reference considered, whether or not classion is in conformance with MPEP 800. Date line through classification in foil in conformance and not considered, include copy of copy of this form with need commencation to agreed. Applicant's expectation separated in agreed as expectation in the conformance of the conform

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.86. The information is required by collection of the information is required by 37 CFR 1.97 and 1.86. The information is required by 32 U.S. C. 120 1.50 CFR 1.97 and 1.86. The information is required by 32 U.S. C. 120 1.50 CFR 1.97 and 1.98 to the information is required by 32 U.S. C. 120 1.50 CFR 1.97 and 1.98 to the information of the inf

PTO/SB/08a (08-03) Approved for usc through 07/31/2006. OMB 0651-0031 U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE o respond to a callectian af information unless it cautains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Under the Paperwark Reduction Act of 1995,

Complete if Known Application Number 10/591,442 Filing Date September 01, 2006 Dena LESHKOWITZ First Named Inventor Group Art Unit 1653

						ap Ait Offit	1033		
		(use as many shee	ts as necessar	v) .	Exa	miner Name	Not Yet A	ssigned	
Sheet			Of	4	Atto Num	rney Docket	32488		
		OTHER	PRIOR ART	- NON PATE	T LITERATI	JRE DOCUMEN	ITS		
Zvaminar	Cite	Include name of the	author (in CAP)	ITAL LETTERS) t	tle of the article (	when annronriate), tit	le of the item		
xaminer Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.						s), publisher,	$T^2$		
23 Mockridge et al. "Common Patterns of B Cell Perturbation and Expanded V4-34									
/CW/	1								
		Immunoglobulin Gene Usage in Autoimmunity and Infection", Autoimmunity, 37(1): 9-15, 2004. Abstract.							
	24				uta Dagantan I	Discounity of Mundo	io Agido		
	24	Ogle et al. "Direct Measurement of Lymphocyte Receptor Diversity", Nucleic Acids							
		Research, 31(22):1-6, 2003.  Ohlin et al. "The Human Antibody Repertoire to Infectious Agents: Implications for							
1	25	Ohlin et al. "Th	e Human Ant	ibody Repertoir	e to Infectious	Agents: Implica	tions for		
		Disease Pathog	enesis", Mole	cular Immunolo	gy, 40:1-11, 2	003			
	26	Pascual et al. "I	Ieavy Chain '	Variable Region	Gene Utilizat	ion in Human Ar	tibodies",		
1		International Re							
	27	Preparata et al.	"Sequencing-	by-Hybridizatio	n at the Inforn	nation - Theory E	Bound: An		
		Optimal Algori	thm". Journal	of Computation	al Biology, 7(	3/4):621-630, 20	00.		
	28	Optimal Algorithm", Journal of Computational Biology, 7(3/4):621-630, 2000.  Quackenbush "Microarray Data Normalization and Transformation", Nature Genetics							
	120	Supplement, 32:496-501, 2002.							
	29	Supplement, 32:496-501, 2002.  Quintana et al. "Functional Immunomics: Microarray Analysis of IgG Autoantibody							
1	29	Quintana et al. "runctional Immunomics: Microarray Analysis of 180 Autoantibody Repertoires Predicts the Future Response of Mice to Induced Diabetes", Proc. Natl. Acad. Sci. USA, P.1-7, 2004.							
1	1								
	1	Risitano et al. "In-Vivo Dominant Immune Responses in Aplastic Anaemia: Molecular							
1	30	Tracking of Putatively Pathogenetic T-Cell Clones by TCR Beta-CDR3 Sequencing",							
1									
		http://www.thelancet.com, 364:355-364, 2004.  Ritgen et al. "Unmutated Immunoglobulin Variable Heavy-chain Gene Status							
- 1	31								
- 1		Remains an Adverse Prognostic Factor After Autologous Stem Cell Transplantation							
1	1	for Chronic Lymphocytic Leukemia", Blood, 101(5): 2049-2053, 2003.							
	32	Sade et al. "The Effect of Specific Immunotherapy on T-Cell Receptor Repertoire in							
1		Patients With Allergy to House-Dust Mite", Allergy, 58:430-434, 2003.							
	33	Shendure et al. "Advanced Sequencing Technologies: Methods and Goals", Nature							
	1	Reviews, 5:335							
	34	Shi "Enabling Large-Scale Pharmacogenetic Studies by High-Throughput Mutation							
- 1	"	Detection and Genotyping Technologies", Clinical Chemistry, 47(2):164-172, 2001.							
	35	Sims et al. "Somatic Hypermutation and Selection of B Cells in Thymic Germinal							
1	33	Sims et al. "Somatic Hypermutation and Selection of B Cells in Thymic Germinal							
1	1	Centers Responding to Acetylcholine Receptor in Myasthenia Gravis", Journal of							
		Immunology, 167:1935-1944, 2001.							
- 1	36	Tobin et al. "Subsets With Restricted Immunoglobulin Gene Rearrangement Features							
1		Indicate A Role for Antigen Selection in the Development of Chronic Lymphocytic							
		Leukemia", Blood, 104(9):2879-2885, 2004.							
	37	Tobin et al. "V(H)3-21 Gene Usage in Chronic Lymphocytic Leukemia					i		
	1	Characterization of A New Subgroup With Distinct Molecular Features and Poor							
		Survival", Leul	kemia and Ly	mphoma, 45(2):	221-228, 200-	4. Abstract.			
Evaminer Date 04//				/10/2008					
Signature	i	/(	Cynthia Wild	er/		Considered	04	1012000	
Signature					1aerea				

\*EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered, include copy of one to firm with next communication to applicant. \*Applicants unique clastion designation number (ceptoral). \*See Kinds Codes of USPTO Patent Documents at year, y Translation is attached.

ransation is attacked.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 38 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to size 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. There will way depending upon the individual case Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Chicer, U.S. Patient and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, WA 22313-1450. DN ROT SEND TESS OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031

Approved for use through 0/31/2000 MERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Poperwork Reduction Act of 1995, no personnel to a collection of information unless it contains a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

JUN 26 2007

					Group Art Unit	1653	
	(	use as many sheet	s as necessary)		Examiner Name	Not Yet Assigned	
Sheet		Of 4 Attorney Docket 32488 Number 32488				32488	
		OTHER	PRIOR ART - NO	N PATENT LITE	RATURE DOCUMENT	S	
Examiner Initials	Cite No.1	Include name of the (book, magazine, jo	author (in CAPITAL LE urnal, serial symposium, city and/	TTERS), title of the a catalog, etc.) date, pa or country where publ	uticle (when appropriate), title ge(s), volume-issue number(s) ished.	of the item , publisher, T <sup>2</sup>	
/CW/	38	Van Dam et al. "Gene Expression Analysis with Universal n-mer Arrays", Cold Spring Harbor Laboratory Press, Genome Research, 12: 145-152, 2002.					
/CW/	39					ons in	
	1 =						
							_
	_						_
	1						

Examiner	/Cynthia Wilder/	Date	04/10/2008
Signature	,	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and net considered, include copy of copy of this form with next control

Internations is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the TUSPTO) to process) an application. Confidentially is governed by 39 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to corriginal, including aphening, preparing, and submitting the completed application from the full PFIO. The wall were provided to the process of the provided application from the full PFIO. The wall was provided and the provided application from the full PFIO. The wall was provided and the provided application from the full PFIO. The wall was provided and the p